We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Clotting Assay Predicts Patient Transfusion Needs

By LabMedica International staff writers
Posted on 30 May 2017
Print article
A new test that quantifies clotting ability can help identify trauma patients who are most in need of a massive blood transfusion, according to a new study.

The new test, developed by researchers at the University of Colorado School of Medicine, modifies thrombelastography (TEG)--a test that measures the viscoelastic properties of whole blood to determine the ability of blood to clot--by adding tissue plasminogen activator (tPA) to the blood sample. As tPA saturates endogenous inhibitors, systemic hyperfibrinolysis occurs, which can help stratify the underlying degree of shock and identify early coagulation changes in order to predict progression to massive transfusion.

To test this hypothesis, the researchers analyzed blood samples from 324 trauma patients, of which 17% required a massive blood transfusion. Trauma activations were analyzed using rapid TEG and the modified TEG-tPA test. Clinical scores, which included shock index, assessment of blood consumption, and trauma-associated severe hemorrhage were then compared with TEG measurements to predict the need for massive transfusion, using areas under the receiver operating characteristic curves.

The results showed that rapid TEG and tPA-TEG parameters were significantly different in all massive transfusion patients compared to non-massive transfusion patients. Low-dose tPA lysis at 30 minutes had the largest the area under the receiver operating characteristic curve for prediction of massive transfusion, similar to the international normalized ratio (INR) of prothrombin time. When the tPA-TEG assay was used together with INR, it improved identification of patients in need of transfusion by 40%, and identified 97% of patients who did not, thereby preventing unnecessary transfusions. The study was published on May 15, 2017, in JACS.

“The tPA-TEG identifies trauma patients who require massive transfusion efficiently in a single assay that can be completed in a shorter time than other scoring systems, which has improved performance when combined with international normalized ratio,” concluded lead author Hunter B. Moore, MD, of the department of surgery. “This new method is consistent with our understanding of the molecular events responsible for trauma-induced coagulopathy.”

TEG is performed by gently rotating a blood sample through approximately 5º six times a minute in order to imitate sluggish venous flow and to activate coagulation. The speed at which the sample coagulates on a thin wire probe depends on the activity of the plasma coagulation system, platelet function, fibrinolysis, and other factors. The patterns of changes in strength and elasticity in the clot provide information about how well the blood can perform hemostasis, and how well or poorly different factors are contributing to clot formation.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.